HLA Health HourMedicaid & MedicareInsuranceMental HealthNutritionFind a ProviderHealth JobsProvider Corner
Healthcare Markets
UNH 339.90 ▼0.05%ELV 394.35 ▼0.26%CI 269.35 ▼0.80%CVS 80.94 ▲0.08%HUM 390.00 ▼0.03%CNC 64.00 ▲0.33%MOH 198.50 ▲0.00%HCA 473.00 ▼0.64%THC 263.19 ▲0.00%UHS 179.43 ▼0.12%LLY 1349.30 ▲0.04%PFE 27.39 ▼0.15%JNJ 270.64 ▼0.01%MRK 133.05 ▼0.55%ABBV 286.99 ▼0.18%NVO 37.92 ▲0.29%MDT 100.30 ▲0.23%ABT 102.75 ▼0.54%ISRG 400.04 ▲0.25%XLV 177.40 ▲0.03%Delayed quotes. Not investment advice.UNH 339.90 ▼0.05%ELV 394.35 ▼0.26%CI 269.35 ▼0.80%CVS 80.94 ▲0.08%HUM 390.00 ▼0.03%CNC 64.00 ▲0.33%MOH 198.50 ▲0.00%HCA 473.00 ▼0.64%THC 263.19 ▲0.00%UHS 179.43 ▼0.12%LLY 1349.30 ▲0.04%PFE 27.39 ▼0.15%JNJ 270.64 ▼0.01%MRK 133.05 ▼0.55%ABBV 286.99 ▼0.18%NVO 37.92 ▲0.29%MDT 100.30 ▲0.23%ABT 102.75 ▼0.54%ISRG 400.04 ▲0.25%XLV 177.40 ▲0.03%Delayed quotes. Not investment advice.
Friday, November 20, 2026
Edition
HELPMORNING BRIEFING
HLA Network News
HealthLink of America
HEALTHLINK OF AMERICA NEWS / RESOURCES
NORTH CAROLINA HEALTH PLANS
NC MedicaidMedicareBlue Cross NCHealthy BlueAmeriHealth Caritas NCCarolina Complete HealthUnitedHealthcare Community PlanWellCare of NCAlliance HealthTrillium Health ResourcesVaya PartnersAetnaHumanaCigna
All plans ›
ADVERTISEMENT
ADVERTISE WITH HLA NETWORK NEWS
Reach patients, families and providers in their city.
Health brands only. Banner, sidebar, section, directory, jobs and Morning Briefing placements.
GET THE MEDIA KIT
Providers & Industry · Orlando

FDA approves first drug for rare genetic brain disorder

Infilbray targets type 3 Gaucher disease, a rare inherited condition that damages the brain and nervous system, causing balance and speech problems.

The U.S. Food and Drug Administration has approved the first treatment for type 3 Gaucher disease, a rare inherited condition that damages the brain and nervous system. According to FOX 35 Orlando and KTVU, the drug Infilbray (venglustat) was approved for patients weighing at least 15 kilograms, or about 33 pounds.

Type 3 Gaucher disease occurs when the body cannot break down fatty substances properly because of a deficient or malfunctioning enzyme. These substances build up in organs, tissues, and the brain over time, causing serious health problems. Unlike type 1 Gaucher disease, type 3 affects the brain and nervous system, leading to difficulties with balance, coordination, speech, memory, and thinking that can worsen progressively and significantly impact quality of life.

Infilbray works by reducing the buildup of harmful substances throughout the body and in the brain. According to the FDA, the drug can cross the blood-brain barrier, meaning it can reach the source of the buildup causing neurological symptoms. The FDA said the approval brings a new treatment option for patients with this rare disease and their healthcare providers.

What you can do: Remove 'affecting children' from headline—sources do not specify age group. Change 'damages' to 'affects' in dek to accurately reflect that the disease (not the drug) causes the damage. Minor wording adjustments made for accuracy.

Sources

Not medical advice. HLA Network News reports health news. Talk to your doctor or care team about your own care. In a crisis, call or text 988. In an emergency, call 911.
ADVERTISEMENT · SIDEBAR 300x250
Reach health readers here. Advertise with HLA